Great Lakes Advisors LLC lowered its position in shares of Danaher Co. (NYSE:DHR – Free Report) by 17.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,623 shares of the conglomerate’s stock after selling 2,791 shares during the period. Great Lakes Advisors LLC’s holdings in Danaher were worth $3,127,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also made changes to their positions in the company. Kentucky Retirement Systems Insurance Trust Fund increased its holdings in shares of Danaher by 11.6% during the 4th quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 21,233 shares of the conglomerate’s stock worth $4,874,000 after buying an additional 2,202 shares during the last quarter. ORG Partners LLC increased its holdings in shares of Danaher by 1,212.8% during the 4th quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate’s stock worth $636,000 after buying an additional 2,559 shares during the last quarter. Generate Investment Management Ltd acquired a new stake in shares of Danaher during the 4th quarter worth approximately $8,044,000. Stifel Financial Corp increased its holdings in shares of Danaher by 1.3% during the 3rd quarter. Stifel Financial Corp now owns 847,348 shares of the conglomerate’s stock worth $235,583,000 after buying an additional 11,216 shares during the last quarter. Finally, Compass Capital Management Inc. increased its holdings in shares of Danaher by 4.8% during the 4th quarter. Compass Capital Management Inc. now owns 237,922 shares of the conglomerate’s stock worth $54,615,000 after buying an additional 10,994 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.
Insider Activity at Danaher
In related news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 11.10% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
View Our Latest Stock Report on DHR
Danaher Price Performance
Danaher stock opened at $211.09 on Friday. The stock has a market cap of $150.87 billion, a P/E ratio of 39.98, a price-to-earnings-growth ratio of 2.66 and a beta of 0.82. The company has a fifty day simple moving average of $220.07 and a 200-day simple moving average of $240.82. Danaher Co. has a 12-month low of $196.80 and a 12-month high of $281.70. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31.
Danaher (NYSE:DHR – Get Free Report) last released its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter in the previous year, the company posted $2.09 earnings per share. Equities analysts expect that Danaher Co. will post 7.63 EPS for the current fiscal year.
Danaher Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be given a $0.32 dividend. The ex-dividend date is Friday, March 28th. This is a boost from Danaher’s previous quarterly dividend of $0.27. This represents a $1.28 dividend on an annualized basis and a yield of 0.61%. Danaher’s payout ratio is 24.24%.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read More
- Five stocks we like better than Danaher
- Best Stocks Under $10.00
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- Stock Analyst Ratings and Canadian Analyst Ratings
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- Investing in Travel Stocks Benefits
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.